Asper Biotech’s new collaboration project

Asper Biotech is participating in a new collaboration project PREDICTION-ADR – Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions. The new European-wide study led by the University of Dundee is set to investigate whether genetic research could be used to predict the side effects of statins and ACE inhibitors.

“Statins and ACE inhibitors are the most effective drugs at preventing cardiovascular disease, but they need to be used better,” said Professor Colin Palmer, from the University of Dundee, who is leading the study.

With the advent of affordable whole genome sequencing, genetic research is now at the point where it can be effectively used to identify `biomarkers’ which signal whether a patient can take the drugs safely or not.

The aim of the trial is to identify reliable biomarkers, which could then be developed into a commercially available clinical test. Partners of the study include the Universities of Liverpool, Utrecht, Uppsala and the private sector firm PGXIS. The study is funded with a €3million grant through the European Union FP7 Health project.

Another step towards the personal medicine

An article of Asper Biotech’s participation of a cancer research project CTCtrap (circulating tumour cells) was just realised in the biggest Estonian newspaper. The CTCtrap method investigates the possibility of “catching” free circulating cancer cells from the bloodstream. In case of a success, this method could possibly lead to a solution where cancer, once beaten, would never return.

Anu Aaspõllu a senior scientist in Asper Biotech told that CTCtrap method would help to improve the cancer diagnostics and treatment significantly and is another step towards the personal medicine. The whole international study of eleven partners from seven countries is led by Leon Ter­stappen a professor of Medical Cell Biophysics of the University of Twente, The Netherlands. European Union is funding the research with 6 million Euros whilst the whole budget is much larger as all the partners must contribute from their side as well.

In case you are fluent in Estonian, you can read more from